Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Replimune's approval is the payoff of a story we have tracked since June, and it lands almost exactly where we said it would. Two rejections. FDA reviewers calling the data package not interpretable days before the hearing. Shares down about a third going in. Then a 10 to 3 advisory vote against the agency's own scientists, and now accelerated approval.

We wrote on Thursday that when the FDA is internally divided, the adcomm is close to a coin flip and briefing documents are not destiny. This is the cleanest possible confirmation. The panel weighed a 24.2% response rate in patients with almost no options, decided the unmet need justified the uncertainty, and the agency followed.

The lesson for anyone modeling regulatory risk is that hostile briefing documents create variance, not verdicts, and the market consistently overprices them as final. Replimune shareholders who sold into that slump learned it expensively.

This week we are watching something different: capital is moving from pipeline to plumbing. Three infrastructure deals just landed. We will pay that off Friday. 👉 Read Full Analysis

🔬 Oncology and Regulatory

Replimune got its approval on the third try, over its own regulator's objections. REPL

The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma who progressed on an anti PD-1 based regimen. Tudriqev is an engineered oncolytic virus injected directly into tumors, where it replicates, destroys cancer cells, and provokes an immune response.

The approval rests on the IGNYTE trial, which enrolled 140 patients with 91 in the efficacy evaluable group, showing a 24.2% objective response rate and a median duration of response of 14.1 months. Both earlier rejections centered on the single arm design, which the agency argued made it impossible to separate Tudriqev's effect from nivolumab's. The advisory committee voted 10 to 3 on July 30 that the results were clinically meaningful, and dissenters focused on that same design question.

This is accelerated approval, so it is provisional. Replimune must verify clinical benefit in a confirmatory trial, and the ongoing Phase 3 will decide whether the approval holds. Reporting from STAT puts the list price at $450,000 for a full course before rebates and discounts, which Replimune has not confirmed publicly.

🏢 M&A

The biggest deals right now are not for drugs. They are for the infrastructure underneath them. LNTH

Curium agreed to acquire Lantheus in a transaction worth up to approximately $8.0 billion, paying $102.50 per share in cash at closing plus up to $12.00 per share in contingent value rights tied to commercial milestones through 2030. That totals up to $114.50 per share, a 38% premium to the unaffected 60 day average. The combined company would span radiodiagnostics and theranostics across more than 70 countries, and Lantheus goes private on closing, expected in the first half of 2027.

The logic is worth noticing. Lantheus's lead product is Pylarify, the prostate cancer imaging agent that determines which patients qualify for radioligand therapy. Curium did not buy another therapy. It bought the diagnostic that gates access to therapy.

That fits a pattern from the same stretch. Nordic Capital agreed to buy BWXT's medical isotope business for up to $800 million, and KKR took medtech contract manufacturer Integer private. Isotope supply, contract manufacturing, and the diagnostics that gate treatment eligibility are all infrastructure, and all three drew serious capital in a matter of days.

Tarsus is buying its way into a rare eye disease. TARS

Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals, gaining gildeuretinol, an investigational once daily oral therapy for Stargardt disease, an inherited retinal condition that causes progressive vision loss in young people and has no approved treatment. For an eye care specialist built on a commercial dry eye franchise, it is a move into genuine unmet need.

📈 Capital Markets

The IPO window is not just open. It is the best in five years.

Drug startups have raised $6 billion through IPOs so far in 2026, more than the combined total at this point in the previous four years, and five more biotechs lined up to price, potentially adding over $1 billion. After a long drought, the public market is functioning again for biotech.

The caveat we keep returning to holds. The capital is concentrated in companies far enough along to look de risked, while preclinical and early stage companies still struggle. Amgen's disclosure last week that its business development is shifting toward earlier stage assets is the first real sign that may correct.

💉 Vaccines

The first mRNA flu shot cleared. MRNA

Moderna's mRNA based seasonal influenza vaccine was cleared, making it the first preventive flu shot built on the technology and completing what BioPharma Dive called a dramatic regulatory turnaround. The significance is platform level. COVID proved mRNA works in an emergency. A seasonal flu vaccine proves it can compete in a routine, established commercial market against entrenched products, and it makes combination respiratory vaccines a realistic next step.

🌍 China and Global

A Chinese biotech won approval in a hard to treat bile duct cancer.

TransThera Sciences' Yochanra (tinengotinib) was approved in China for adults with advanced, metastatic, or unresectable cholangiocarcinoma carrying an FGFR2 fusion or rearrangement, who have already received systemic therapy and an FGFR inhibitor. Bile duct cancer is aggressive and poorly served, and the post FGFR inhibitor setting is narrower still.

Separately, Biocon launched Yesafili (aflibercept-jbvf) commercially in the US, adding biosimilar pressure in ophthalmology.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

📋 The Week in Review

👉 Read Full Analysis

Tudriqev's approval closes a regulatory saga worth studying, because it produced a specific, transferable lesson about how to model agency risk in the current environment.

Reconstruct the sequence. Replimune submitted, was rejected. Submitted again, rejected again. Both rejections turned on the same objection, that a single arm trial combining Tudriqev with nivolumab could not isolate Tudriqev's contribution. That is a legitimate methodological concern, and under the previous commissioner the agency defended it publicly. After that leadership changed, Replimune negotiated a path forward, refiled in June, and the agency committed to a compressed review. Days before the advisory meeting, FDA reviewers released briefing documents calling the data package not interpretable, and the stock fell roughly a third. The panel then voted 10 to 3 against the agency's own reviewers, and approval followed.

The transferable lesson is about variance. The conventional model treats negative briefing documents as close to determinative, and the market prices them that way, which is why Replimune lost a third of its value on documents rather than on data. But when an application involves a genuinely contested methodological question and a population with few options, the advisory panel is weighing something the reviewers are not, namely whether the uncertainty is acceptable given the alternative of nothing. Clinicians and patient advocates carry real weight in that calculation. The FDA explicitly cited input from clinical experts and patient advocates in its approval announcement.

How to apply it. First, for drugs in refractory settings with no good options, discount hostile briefing documents more than the market does. The unmet need argument has independent force. Second, watch the composition and the public hearing portion of the adcomm, because that is where the unmet need case gets made. Third, treat accelerated approval as a conditional outcome rather than a finish line, since the confirmatory trial can still undo it, which is precisely the risk Replimune now carries into its Phase 3 readout.

The broader read on the agency stands. It is improvising, division by division, without a settled philosophy, and that produces both the Capricor no and the Replimune yes in the same week. Unpredictability is the operating environment, and the practical response is wider outcome ranges in your models, not a directional bet on whether the agency has turned friendly or hostile.

💊 Why Capital Is Buying Plumbing

Three infrastructure deals in a matter of days, Curium and Lantheus at up to $8 billion, Nordic Capital and BWXT's isotope business at up to $800 million, and KKR taking medtech manufacturer Integer private, is not coincidence. It reflects a coherent investment thesis worth understanding.

The thesis is that infrastructure captures value with less binary risk than drug development. A therapeutic program either works or it does not, and most do not. The companies supplying isotopes, contract manufacturing, and diagnostics get paid across the whole field regardless of which specific molecules succeed. In a period when drug developers are flush and running more programs than ever, the suppliers sit in an unusually strong position.

The Curium and Lantheus logic is the sharpest illustration. Radioligand therapy is one of oncology's fastest growing modalities, but it depends on a supply chain that is genuinely hard to build, isotope production, short half life logistics, and specialized manufacturing. It also depends on diagnostics, because patients must be imaged to determine eligibility for the therapy. Lantheus's Pylarify is the prostate imaging agent that performs exactly that gating function. Curium bought the toll booth rather than another car.

The same reasoning explains the other two. Medical isotopes are a genuine bottleneck with limited global supply and high barriers to entry. Contract manufacturing in medtech serves everyone and is insulated from any single product's fate.

What consolidates next. The most attractive remaining targets share three traits: they serve a modality that is scaling, they are hard to replicate, and customers cannot easily substitute them. That points to specialty reagents, single use bioprocessing components, peptide manufacturing capacity given the GLP-1 boom, sterile fill and finish, and cold chain logistics for cell and gene therapy. Samsung Biologics buying PolyPeptide for $1.8 billion and Repligen buying BioLife for $1.5 billion in late July fit the same pattern. If you run a differentiated mid sized business in any of those segments, strategic interest in you is as high as it has been in years, and the private equity bid is now competing with the strategic bid, which is what pushes multiples up.

📊 The IPO Window, and Who Still Cannot Get Through It

Biotech IPOs raising $6 billion so far in 2026, more than the previous four years combined at this stage, is the clearest evidence yet that the sector's capital markets have genuinely reopened. Five more companies lined up to price could add over a billion.

What reopened it. A combination of factors we have tracked all year: record M&A creating visible exit paths, a friendlier regulatory posture producing approvals, strong earnings across large cap pharma, and a backlog of companies that delayed offerings through the drought and now have more mature assets than a typical IPO cohort.

That last point is also the limitation. The companies getting through are disproportionately those with clinical data, often late stage, which is precisely the profile the private markets have also been favoring. The window is open, but it is open for de risked companies. A preclinical company with compelling science and no human data is not going public in this market, and it is struggling to raise privately too, with roughly two thirds of first half venture rounds going to companies that already had a drug in humans.

So the correct read is not that biotech financing has recovered. It is that biotech financing has recovered for one half of the barbell. The late stage end is genuinely healthy across public and private markets. The early stage end remains the tightest it has been in years, which mortgages the supply of acquisition targets in the 2030s.

The thing to watch is whether Amgen's stated shift toward earlier stage business development spreads. If several large caps conclude, as Amgen apparently has, that the late stage assets are too expensive and the differentiated opportunity sits earlier, that redirects real capital and strategic attention toward the starved end of the barbell. That would be the correction the sector needs, and obesity is the most likely place for it to start because the prize justifies the risk. One company saying it is not a trend. Watch for the second and third.

🎯 Catalyst Calendar

Replimune won on the third try and proved that hostile briefing documents are not verdicts. Meanwhile the biggest checks are being written for isotopes, imaging agents, and manufacturing rather than molecules. That is our thread this week. What are you watching? Reply to this email.

👉 Visit The Pro Hub

Sponsorship slots for 2026 are limited. See packages and pricing →